Printer Friendly
The Free Library
19,573,952 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Acrongenomics Inc. Continues Negotiations for the Acquisition of Molecular Vision Ltd.


GENEVA, Switzerland Switzerland (swĭt`sərlənd), Fr. Suisse, Ger. Schweiz, Ital. Svizzera, officially Swiss Confederation, federal republic (2005 est. pop. 7,489,000), 15,941 sq mi (41,287 sq km), central Europe.  -- Further to the company's announcement dated February 14th 2008 for the remaining acquisition of Molecular Vision, Ltd., Acrongenomics, Inc. (OTCBB OTCBB

See OTC Bulletin Board (OTCBB).
:AGNM) today announces that the negotiations are still ongoing.

"We are working with Molecular Vision to finalize fi·nal·ize  
tr.v. fi·nal·ized, fi·nal·iz·ing, fi·nal·iz·es
To put into final form; complete or conclude: "They have jointly agreed ...
 the agreement in the very near future", commented Dr. Dimitri Goundis, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  of Acrongenomics.

About Acrongenomics:

Acrongenomics Inc. is a publicly traded company publicly traded company

A company whose shares of common stock are held by the public and are available for purchase by investors. The shares of publicly traded firms are bought and sold on the organized exchanges or in the over-the-counter market.
 that focuses on investing in and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, consumer-orientated applications. The company has its headquarters in Geneva, Switzerland.

About Molecular Vision:

Molecular Vision is an Imperial College spin-out company that develops low-cost diagnostic devices for use in the doctor's surgery and in the home. Its proprietary devices combine microfluidic chips with organic-semiconductor light-sources and photodetectors to provide lab-quality diagnostic tests in a miniaturised, easy-to-use, disposable disposable Nursing adjective Referring to that which is discarded or disposed of noun An item used in health care-related Pt contact which is discarded after use–eg masks, gloves, gowns, needles, paper products, syringes, wipes. See Biohazardous waste.  format.

Important Information About Forward-Looking Statements forward-looking statement

A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections.
 

All statements in this news release that are other than statements of historical facts are forward-looking statements which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward- looking statements by using words such as "anticipates", "believes", "could", "expects", "intends", "may", "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price Trading price

The price at which a security is currently selling.
 and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions. For further information concerning risks and uncertainties that may affect our future results, please review the disclosures contained in our latest filings with the SEC, including our most recent annual report on Form 10-KSB, and subsequent quarterly reports on Form 10-QSB. Other than as required by federal securities laws, we undertake no obligation to publicly update or revise any of our forward- looking statements, whether as a result of changed circumstances CIRCUMSTANCES, evidence. The particulars which accompany a fact.
     2. The facts proved are either possible or impossible, ordinary and probable, or extraordinary and improbable, recent or ancient; they may have happened near us, or afar off; they are public or
, new information, future events, or for any other reason occurring after the date of this news release.
COPYRIGHT 2008 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Apr 3, 2008
Words:425
Previous Article:Expanding Obese Population and Improved Technology with Faster Outcomes Pump up the U.S. Market for Obesity Surgery Devices.
Next Article:Research and Markets: New CHS: Company Profile Offers a Comprehensive Analysis of the Organization, their Business Segments and Competitors.



Related Articles
Executive Briefing
NETGENICS ACQUIRES CHEMSYMPHONY/METASYMPHONY FROM FAMILYGENETIX.
NETGENICS ACQUIRES CHEMSYMPHONY/METASYMPHONY FROM FAMILYGENETIX.
Thermo Electron Subsidiary Acquires Company.
Oxford Molecular Sells Businesses.
FAMILYGENETIX REALIGNS PRODUCT OFFERINGS.
BioForce receives nanoarray patent.
Feel the vibrations.
Invitrogen picks up two new businesses.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles